Dicerna Pharmaceuticals Submits Investigational New Drug (IND) Application for DCR-PH1, an Investigational Therapy for Primary Hyperoxaluria Type 1 (PH1)

September 02, 2015 at 07:30 AM EDT

Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA), a leading developer of RNA interference (RNAi) therapeutics, today announced the ...